Favorable response to PD-1 inhibitor plus chemotherapy as first-line treatment for metastatic follicular dendritic cell sarcoma of the spleen: a case report

Follicular dendritic cell sarcoma (FDCS) is an uncommon low-grade malignant sarcoma. For localized FDCS, surgery is the most commonly recommended therapy option. However, there is no standard treatment protocol for metastatic FDCS. Here, we present a 68-year-old female with primary spleen FDCS who h...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jielang, Ren, Min, Bi, Feng, Chen, Ye, Li, Zhiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485249/
https://www.ncbi.nlm.nih.gov/pubmed/37691960
http://dx.doi.org/10.3389/fimmu.2023.1228653
_version_ 1785102742934519808
author Li, Jielang
Ren, Min
Bi, Feng
Chen, Ye
Li, Zhiping
author_facet Li, Jielang
Ren, Min
Bi, Feng
Chen, Ye
Li, Zhiping
author_sort Li, Jielang
collection PubMed
description Follicular dendritic cell sarcoma (FDCS) is an uncommon low-grade malignant sarcoma. For localized FDCS, surgery is the most commonly recommended therapy option. However, there is no standard treatment protocol for metastatic FDCS. Here, we present a 68-year-old female with primary spleen FDCS who had multiple peritoneal metastases. She was treated with sintilimab (PD-1 inhibitor) plus chemotherapy (epirubicin plus ifosfamide) as first-line treatment achieving partial response (PR) and a relatively long progression-free survival (PFS) of 17 months. This case suggests that PD-1 inhibitor plus chemotherapy as first-line therapy seem to be a promising treatment option for metastatic FDCS.
format Online
Article
Text
id pubmed-10485249
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104852492023-09-09 Favorable response to PD-1 inhibitor plus chemotherapy as first-line treatment for metastatic follicular dendritic cell sarcoma of the spleen: a case report Li, Jielang Ren, Min Bi, Feng Chen, Ye Li, Zhiping Front Immunol Immunology Follicular dendritic cell sarcoma (FDCS) is an uncommon low-grade malignant sarcoma. For localized FDCS, surgery is the most commonly recommended therapy option. However, there is no standard treatment protocol for metastatic FDCS. Here, we present a 68-year-old female with primary spleen FDCS who had multiple peritoneal metastases. She was treated with sintilimab (PD-1 inhibitor) plus chemotherapy (epirubicin plus ifosfamide) as first-line treatment achieving partial response (PR) and a relatively long progression-free survival (PFS) of 17 months. This case suggests that PD-1 inhibitor plus chemotherapy as first-line therapy seem to be a promising treatment option for metastatic FDCS. Frontiers Media S.A. 2023-08-25 /pmc/articles/PMC10485249/ /pubmed/37691960 http://dx.doi.org/10.3389/fimmu.2023.1228653 Text en Copyright © 2023 Li, Ren, Bi, Chen and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Li, Jielang
Ren, Min
Bi, Feng
Chen, Ye
Li, Zhiping
Favorable response to PD-1 inhibitor plus chemotherapy as first-line treatment for metastatic follicular dendritic cell sarcoma of the spleen: a case report
title Favorable response to PD-1 inhibitor plus chemotherapy as first-line treatment for metastatic follicular dendritic cell sarcoma of the spleen: a case report
title_full Favorable response to PD-1 inhibitor plus chemotherapy as first-line treatment for metastatic follicular dendritic cell sarcoma of the spleen: a case report
title_fullStr Favorable response to PD-1 inhibitor plus chemotherapy as first-line treatment for metastatic follicular dendritic cell sarcoma of the spleen: a case report
title_full_unstemmed Favorable response to PD-1 inhibitor plus chemotherapy as first-line treatment for metastatic follicular dendritic cell sarcoma of the spleen: a case report
title_short Favorable response to PD-1 inhibitor plus chemotherapy as first-line treatment for metastatic follicular dendritic cell sarcoma of the spleen: a case report
title_sort favorable response to pd-1 inhibitor plus chemotherapy as first-line treatment for metastatic follicular dendritic cell sarcoma of the spleen: a case report
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485249/
https://www.ncbi.nlm.nih.gov/pubmed/37691960
http://dx.doi.org/10.3389/fimmu.2023.1228653
work_keys_str_mv AT lijielang favorableresponsetopd1inhibitorpluschemotherapyasfirstlinetreatmentformetastaticfolliculardendriticcellsarcomaofthespleenacasereport
AT renmin favorableresponsetopd1inhibitorpluschemotherapyasfirstlinetreatmentformetastaticfolliculardendriticcellsarcomaofthespleenacasereport
AT bifeng favorableresponsetopd1inhibitorpluschemotherapyasfirstlinetreatmentformetastaticfolliculardendriticcellsarcomaofthespleenacasereport
AT chenye favorableresponsetopd1inhibitorpluschemotherapyasfirstlinetreatmentformetastaticfolliculardendriticcellsarcomaofthespleenacasereport
AT lizhiping favorableresponsetopd1inhibitorpluschemotherapyasfirstlinetreatmentformetastaticfolliculardendriticcellsarcomaofthespleenacasereport

Ejemplares similares